Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L32 pseudogene 2 (RPL32P2) is a human processed pseudogene, meaning it is a non-functional DNA sequence derived from the ribosomal protein L32 (RPL32) gene by retrotransposition. Unlike its parent gene RPL32, which encodes a protein component of the ribosomal 60S subunit involved in translation, RPL32P2 does not encode any protein and lacks evidence of biological activity. It is cataloged on chromosome 9 and is one among numerous ribosomal protein pseudogenes scattered throughout the human genome. There are no documented biological functions, disease associations, or therapeutic implications for RPL32P2. Pseudogenes such as RPL32P2 arise through DNA duplication or retrotransposition but generally do not produce functional proteins. Ribosomal protein pseudogenes are abundant in mammalian genomes, but the majority are not active and are considered genomic "fossils". The functional ribosomal protein L32 gene (RPL32) is important for ribosome structure and function, but its pseudogenes like RPL32P2 have no therapeutic relevance. This pseudogene is not considered a therapeutic target; it does not encode a functional protein and is classified as a pseudogene. It is not a typical drug target; while the gene symbol and name are correct, the use as a target is inappropriate. If the intent was to refer to the parent ribosomal protein L32 (RPL32), that is a distinct functional protein, not the pseudogene in question. RPL32P2 itself is not documented in regulatory roles like some other pseudogenes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L32 pseudogene 2 (RPL32P2).